REDUCTION OF CUMULATIVE CARDIOVASCULAR RISK IN PATIENTS WITH ARTERIAL HYPERTENSION: THE ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACCORDING TO THE NEW EUROPEAN RECOMMENDATIONS
Conception of total cardio-vascular risk plays important role in defining tactics of arterial hypertension therapy according to the new European recommendations. Choice of antihypertensive therapy is based on meta-analysis of large clinical studies with hard end points. It is recommended to use five...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-12-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/463 |
| _version_ | 1797232350253285376 |
|---|---|
| author | M. N. Mamedov N. A. Chepurina Z. N. Tokareva A. A. Evdokimova |
| author_facet | M. N. Mamedov N. A. Chepurina Z. N. Tokareva A. A. Evdokimova |
| author_sort | M. N. Mamedov |
| collection | DOAJ |
| description | Conception of total cardio-vascular risk plays important role in defining tactics of arterial hypertension therapy according to the new European recommendations. Choice of antihypertensive therapy is based on meta-analysis of large clinical studies with hard end points. It is recommended to use five classes of antihypertensive drugs in mono- and combined therapy. Angiotensin converting enzyme (ACE) inhibitors keep important place in the therapy of arterial hypertension accompanying with risk factors and associated diseases. Enalapril is one of the widely used ACE inhibitors, its efficiency was proved in prospective clinical studies. In high risk patients monotherapy with Enam (enalapril, Dr. Reddy’s) decreases blood pressure and leads to positive metabolic changes. This results in significant risk reduction of cardio-vascular complications. |
| first_indexed | 2024-03-08T14:04:46Z |
| format | Article |
| id | doaj.art-2a03a90041d24bd99ceb62a7baa2fab8 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:58:53Z |
| publishDate | 2015-12-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-2a03a90041d24bd99ceb62a7baa2fab82024-04-01T07:43:26ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-12-0133727610.20996/1819-6446-2007-3-3-72-76463REDUCTION OF CUMULATIVE CARDIOVASCULAR RISK IN PATIENTS WITH ARTERIAL HYPERTENSION: THE ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACCORDING TO THE NEW EUROPEAN RECOMMENDATIONSM. N. Mamedov0N. A. Chepurina1Z. N. Tokareva2A. A. Evdokimova3State Research Center of Preventive Medicine, Roszdrav, MoscowState Research Center of Preventive Medicine, Roszdrav, MoscowState Research Center of Preventive Medicine, Roszdrav, MoscowState Research Center of Preventive Medicine, Roszdrav, MoscowConception of total cardio-vascular risk plays important role in defining tactics of arterial hypertension therapy according to the new European recommendations. Choice of antihypertensive therapy is based on meta-analysis of large clinical studies with hard end points. It is recommended to use five classes of antihypertensive drugs in mono- and combined therapy. Angiotensin converting enzyme (ACE) inhibitors keep important place in the therapy of arterial hypertension accompanying with risk factors and associated diseases. Enalapril is one of the widely used ACE inhibitors, its efficiency was proved in prospective clinical studies. In high risk patients monotherapy with Enam (enalapril, Dr. Reddy’s) decreases blood pressure and leads to positive metabolic changes. This results in significant risk reduction of cardio-vascular complications.https://www.rpcardio.online/jour/article/view/463arterial hypertensionhigh cardio-vascular riskenalapril |
| spellingShingle | M. N. Mamedov N. A. Chepurina Z. N. Tokareva A. A. Evdokimova REDUCTION OF CUMULATIVE CARDIOVASCULAR RISK IN PATIENTS WITH ARTERIAL HYPERTENSION: THE ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACCORDING TO THE NEW EUROPEAN RECOMMENDATIONS Рациональная фармакотерапия в кардиологии arterial hypertension high cardio-vascular risk enalapril |
| title | REDUCTION OF CUMULATIVE CARDIOVASCULAR RISK IN PATIENTS WITH ARTERIAL HYPERTENSION: THE ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACCORDING TO THE NEW EUROPEAN RECOMMENDATIONS |
| title_full | REDUCTION OF CUMULATIVE CARDIOVASCULAR RISK IN PATIENTS WITH ARTERIAL HYPERTENSION: THE ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACCORDING TO THE NEW EUROPEAN RECOMMENDATIONS |
| title_fullStr | REDUCTION OF CUMULATIVE CARDIOVASCULAR RISK IN PATIENTS WITH ARTERIAL HYPERTENSION: THE ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACCORDING TO THE NEW EUROPEAN RECOMMENDATIONS |
| title_full_unstemmed | REDUCTION OF CUMULATIVE CARDIOVASCULAR RISK IN PATIENTS WITH ARTERIAL HYPERTENSION: THE ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACCORDING TO THE NEW EUROPEAN RECOMMENDATIONS |
| title_short | REDUCTION OF CUMULATIVE CARDIOVASCULAR RISK IN PATIENTS WITH ARTERIAL HYPERTENSION: THE ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACCORDING TO THE NEW EUROPEAN RECOMMENDATIONS |
| title_sort | reduction of cumulative cardiovascular risk in patients with arterial hypertension the role of angiotensin converting enzyme inhibitors according to the new european recommendations |
| topic | arterial hypertension high cardio-vascular risk enalapril |
| url | https://www.rpcardio.online/jour/article/view/463 |
| work_keys_str_mv | AT mnmamedov reductionofcumulativecardiovascularriskinpatientswitharterialhypertensiontheroleofangiotensinconvertingenzymeinhibitorsaccordingtotheneweuropeanrecommendations AT nachepurina reductionofcumulativecardiovascularriskinpatientswitharterialhypertensiontheroleofangiotensinconvertingenzymeinhibitorsaccordingtotheneweuropeanrecommendations AT zntokareva reductionofcumulativecardiovascularriskinpatientswitharterialhypertensiontheroleofangiotensinconvertingenzymeinhibitorsaccordingtotheneweuropeanrecommendations AT aaevdokimova reductionofcumulativecardiovascularriskinpatientswitharterialhypertensiontheroleofangiotensinconvertingenzymeinhibitorsaccordingtotheneweuropeanrecommendations |